32 results about "Macrophage inflammatory protein" patented technology

Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR⁷ and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.

The invention provides an ELISA (Enzyme-linked Immunoassay Assay) plate and kit for predicting ALI (Acute Lung Injury)/ARDS (Acute Respiratory Distress Syndrome) and assessing prognosis of the ALI/ARDS. The ELISA plate comprises a solid phase carrier which is provided with a monoclonal antibody of bone morphogenetic protein 15, a monoclonal antibody of CXC chemokine ligand 16, a monoclonal antibody of CXC chemokine receptor 3, a monoclonal antibody of interleukin-6, a monoclonal antibody of nephroblastoma overexpression genes, a monoclonal antibody of insulin-like growth factor binding protein 4, a monoclonal antibody of interleukin-5, a monoclonal antibody of interleukin 5 receptor, a monoclonal antibody of interleukin 22 receptor binding protein, a monoclonal antibody of leptin, a monoclonal antibody of macrophage inflammatory protein-1D, a monoclonal antibody of orexin B, a monoclonal antibody of CC type chemokine receptor 2, a monoclonal antibody of transforming growth factor-beta5 and blank control holes. The ELISA plate and kit can achieve accurate results and are simple to operate.

The invention relates to an application of a non-coding small RNA gene miR-146a in preparing a medicine for curing gastricism. The gastricism can be caused by helicobacter pylori infection. The miR-146a is highly expressed in helicobacter pylori infected gastric epithelial cells and human gastric mucosa tissues; furthermore, after the gastric epithelial cells GES-1 are transfected by a miR-146a simulator or a miR-146a inhibitor respectively, the miR-146a simulator can obviously reduce the protein secretion level of inflammatory factor lnterleukin 8, macrophage inflammatory protein 3Alpha and growth-related oncogene Alpha and the protein secretion level of the macrophage inflammatory protein 3Alpha, thus indicating that the miR-146a can effectively inhibit inflammatory response related to the helicobacter pylori infection.

The invention provides MIP (macrophage inflammatory protein) 3alpha-Fc fusion protein. The fusion protein is macrophage inflammatory protein (MIP3alpha) and dimer fusion protein of Fc; and the MIP3alpha is connected with the Fc through a hinge region or a flexible peptide of immunoglobulin. The invention provides the long-acting MIP3alpha-Fc fusion protein. The fusion protein has good bioactivity and stability in vitro and vivo, and has a chemotaxis effect on immature dendritic cells; after the MIP3alpha-Fc fusion protein is injected into a tumor, growth of the tumor can be inhibited, and the MIP3alpha-Fc fusion protein has long plasma half-life.

The invention belongs to the technical field of biological medicines and particularly relates to a biological marker group for optic neuromyelitis spectrum diseases, application of the biological marker group, a protein chip and a kit. The invention provides an optic neuromyelitis spectrum disease biomarker group which is characterized by comprising monocyte chemotactic protein-3, LIGHT, macrophage inflammatory protein-1 delta, insulin-like growth factor-2, a glucocorticoid induced tumor necrosis factor receptor, thrombopoietin and a herpes virus entry medium, wherein the LIGHT is a lymphotoxin analogue which can be induced and expressed on a T cell and competes with glycoprotein D of HSV to be combined with HVEM. The application fills the blank that no reliable and accurate product and method for diagnosing and identifying optic neuromyelitis lineage diseases exist clinically at present.

The invention discloses application of virus macrophage inflammatory protein vMIP-II for inducing dephosphorylation of CD8<+> T cells to form Tcm. The vMIP-II for inducing dephosphorylation of the CD8<+> T cells to form the Tcm is developed in a laboratory and is verified by the National Institute for Control of Pharmaceutical and Biological Products. According to the invention, the CD8<+> T cellsare researched through a rhesus SIV infection model. The research finds that: the vMIP-II can enable Tcm to be proliferated depending on the dosage of the vMIP-II, and the differential gene of the proliferative cell is mainly enriched in a chemokine receptor and a phosphorylation pathway. The research further finds that: the proliferation is as follows: the vMIP-II closes a CD8<+> T chemokine receptor, promotes low expression of G protein, reduces the concentration of intracellular Ca<2+> and mitochondrial membrane potential, inhibits phosphorylation related genes, and promotes low expressionof phosphorylated proteins ERK1/2 and Akt, so that a CD8<+> T phosphorylation signal is weakened, metabolic reprogramming is carried out, and the CD8<+> T is converted into the Tcm. Therefore, the discovery of the vMIP-II action mechanism provides a brand-new strategy for drug research and development of HIV/SIV infected AIDS, provides a new means for adoptive immunotherapy of virus resistance and tumor resistance, and has important clinical application value.

The invention discloses a solid-phase synthesis method of vMIP-II (viral macrophage inflammatory protein-II) protein, comprising the following steps of: adding dimethyldichlorosilane into a reaction flask, ventilating and staying overnight to silanize the reaction flask, coarsely washing with ethanol and cooling at the temperature of minus 80 DEG C, washing and drying again, weighing resin and placing the resin into the reaction flask, adding three times volume of the resin of DCM (dichloromethane) solution, swelling for 30min and evacuating liquid, and then carrying out amino acid coupling, ninhydrin reaction detection and alpha-amino group deprotection circularly from a terminal C to a terminal N on a polypeptide synthesizer until all the amino acid residues are coupled; after the coupling is completed, taking down the reaction flask and cleaning with the DCM, draining the resin and then cutting with precooled cutting fluid, and purifying the cut polypeptide by adopting HPLC (High Performance Liquid Chromatography), wherein the polypeptide is purified on a Waters600E high pressure liquid phase chromatograph; and carrying out high pressure reversed phase chromatography by adopting a Kromasil100-5C18 pillar, and collecting target peak polypeptide, namely the vMIP-II protein.

The invention belongs to the technical field of molecular biology, and relates to a biomarker composition for detecting a gastric cancer autoantibody and application of the biomarker composition. The biomarker composition can be used for detecting the autoantibody in serum of a patient with gastric cancer. The biomarker combination for detecting the gastric cancer autoantibody comprises macrophage inflammatory protein -3alpha, macrophage inflammatory protein -1beta, a monocyte chemotactic factor -1 and matrix metalloproteinase -9. With the biomarker composition for detecting the gastric cancer autoantibody, the technical defects of low specificity, sensitivity and accuracy of an existing marker for detecting the gastric cancer autoantibody can be eliminated.

The invention belongs to the technical field of biological medicines, and particularly relates to a biomarker group, application thereof, a protein chip, a protein chip kit and an ELISA kit. The provided biomarker group is applied to preparation of a product for diagnosing demyelinating diseases of the central nervous system, and comprises a stromal cell derivative factor-1, granulocyte chemotactic protein 2, mononuclear cell chemotactic protein-1, interleukin-2, gamma-interferon, insulin-like growth factor binding protein-3, E-cadherin and macrophage inflammatory protein-1 delta; and the demyelinating diseases include an aquaporin 4 antibody negative neuromyelitis spectrum disease and an aquaporin 4 antibody negative multiple sclerosis. The blank there is no reliable product and method for diagnosing and identifying multiple sclerosis and neuromyelitis spectrum diseases under negative aquaporin 4 antibody clinically at present is filled.

The genetic engineering tandem expression process of pentadecapeptide originated from virus macropage inflammatory protein II N terminal includes: synthesizing one gene segment including several pentadecapeptides connected through protein cleavage sequence gene by using virus macropage inflammatory protein II N terminal pentadecapeptided as target and in a eukaryotic expression system; adding limiting cleavage sites to the 5' and 3' terminals of the gene segment; connecting the gene segment to plasmid vector by means of gene recombination, converting saccaromycete to screen, express and purify target protein; cleaving the purified protein with protease, and separating and purifying to obtain target polypeptide. The polypeptide can antagonize CXCR4 pentadecapeptide, and has the function of preventing and treating AIDS and wide medicine application foreground.

The invention belongs to the field of tumor necrosis factor-(TNF-)-related apoptosis-inducing ligand (TRAIL). Especially, the invention relates to 7 truncated mutants (AK, E2, E3, E4, DA, BX424 and BX439) of TRAIL. A protein sequence coded by DA is completely same with that of TRAILbeta, and a protein sequence coded by BX424 is completely same with that of TRAILdelta. As a result of experiments, among the truncated mutants, except BX439, the mutants have different degrees of capabilities for activating NF-kappaB. As a result of further studies, over-expressions of DA, BX424 and E4 assist in substantially activating macrophage inflammatory protein-1beta(MIP-1beta/CCL4), macrophage inflammatory protein-3alpha(MIP-3alpha/CCL20), and interleukin8(IL8/CXCL8) promoter reporter gene. The TRAIL mutant provided by the invention has wide application prospect in treating inflammatory responses.

The invention belongs to the field of antisense nucleic acid medicaments, and relates to a macrophage inflammatory protein (MIP) 3 alpha antibody to nuclear antigen (ANA) 6 and preparation thereof to the preparation of immunosuppressive medicaments. The immune response of an organism plays a key role in autoimmune diseases and the exclusive reaction of the transplantation of organs and tissues. The invention provides the antisense nucleic acid molecule MIP3 alpha ANA6 used for preparing the immunosuppressive medicaments. The MIP3 alpha ANA6 is a double-stranded nucleic acid molecule. The sense strand of a DNA sequence of the MIP3 alpha ANA6 is 5'-ATATATTGTGCGTCTCCTC-3', and an antisense strand is 5'-GAGGAGACGCACAATATAT-3'. Under the condition of culture with the addition of inflammatory cytokines, the MIP3 alpha ANA6 can remarkably reduce many kinds of cell expressing MIP3 alpha mRNA and generating MIP3 alpha proteins, and functions in immunosuppression by suppressing antigen presenting cells and T cells. The invention provides the novel antisense nucleic acid medicament for treating MIP3 alpha-related immune diseases.